Clover Health Investments, Corp. filed a Current Report on Form 8-K with the SEC on November 16, 2026, to publish a list of responses to shareholder questions regarding its third quarter 2026 earnings. The filing, which includes an exhibit labeled "Supplemental Shareholder Q&A," provides additional context on the company's long-term strategy, operational efficiency, and the capabilities of its AI platform, Counterpart Health.
In response to a question about long-term projections, management stated that while formal guidance for 2027 and 2028 has not been issued, the company sees a meaningful earnings opportunity through 2028. This opportunity is described as being built upon the growth and clinical investments made in 2025 and 2026. Management noted that the 2025 and 2026 cohorts represent approximately half of the company's current membership, and that these groups move into years where the company has historically seen stronger economics.
The company also addressed its Selling, General, and Administrative (SG&A) ratio, which it noted remains higher than some peers. Management stated that it expects to meet or exceed its initial target of a 100 to 150 basis point improvement year over year for the full year 2026. The company attributes room for improvement to spreading a large fixed cost base across a growing membership base and utilizing AI to build more efficient operations from the ground up.
A significant portion of the Q&A focused on Counterpart Health, the company's proprietary AI platform. Management highlighted that the platform has historically supported care for approximately two-thirds of Clover's membership. The company cited clinical evidence showing that use of the platform was associated with Chronic Kidney Disease (CKD) diagnosis approximately 18 months earlier and a 25% reduction in 30-day readmissions for heart failure patients. Additionally, the company claims a 1,500-basis-point Medical Cost Ratio (MCR) advantage associated with the platform.
Regarding the commercialization of Counterpart Health, management stated that they are not disclosing contracted lives, individual implementation schedules, or financial outlooks at this time. The priority is to demonstrate the platform's value in third-party environments, including Medicare Advantage, Accountable Care Organizations (ACOs), and rural markets, rather than focusing on immediate revenue contribution.
Clover Health also discussed its growth in the New Jersey individual non-SNP Medicare Advantage market. The company reported that it has grown its market share from roughly 20% to 31%, becoming the largest individual non-SNP MA plan in New Jersey on that basis. Management noted that approximately 42% of Medicare beneficiaries in New Jersey are currently enrolled in MA plans, leaving a substantial population in Original Medicare that the company believes could be converted to MA plans over time.